Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer.
Date
2022-08-01ICR Author
Author
Alataki, A
Dowsett, M
Type
Journal Article
Metadata
Show full item recordAbstract
Endocrine therapies are the main treatment strategies for the clinical management of hormone-dependent breast cancer. Despite prolonged time to recurrence in the adjuvant setting and the initial clinical responses in the metastatic setting, many patients eventually encounter tumour relapse due to acquired resistance to these agents. Other patients experience a lack of tumour regression at the beginning of treatment indicating de novo resistance that significantly limits its efficacy in the clinic. There is compelling evidence that human epidermal growth factor receptor-2 (HER2) overexpression contributes to resistance to endocrine therapies in oestrogen receptor-positive (ER+) breast cancer. ER+/HER2+ tumours comprise about 10% of all breast cancer cases and about 60% of the whole set of HER2+ tumours. Most patients with primary ER+/HER2+ disease will receive antibody-based HER2-targeted therapy, but this is generally for no more than one year while endocrine treatment is usually for at least 5 years. A number of HER2-kinase inhibitors are also now in clinical use or in clinical trials, and the interaction of these with endocrine treatment may differ from that of antibody treatment. In this review article, we aim to summarise knowledge on molecular mechanisms of breast cancer resistance to endocrine therapies attributable to the impact of HER2 signalling on endocrine sensitivity, to discuss data from clinical trials addressing the role of HER2 in the development of endocrine resistance in the metastatic, neoadjuvant and adjuvant settings and to explore rational new therapeutic strategies.
Collections
Subject
breast cancer
endocrine therapies
human epidermal growth factor receptor-2
oestrogen receptor
resistance
Antineoplastic Agents, Hormonal
Breast Neoplasms
Endocrine System
Female
Hormones
Humans
Neoplasm Recurrence, Local
Receptor, ErbB-2
Research team
Molecular Oncology
Language
eng
Date accepted
2022-05-25
License start date
2022-08-01
Citation
Endocrine-Related Cancer, 2022, 29 (8), pp. R105 - R122
Publisher
BIOSCIENTIFICA LTD